/MGX
MGX Stock - Metagenomi, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$1.76+6.02%
+$0.10 (+6.02%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.27
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+723.9%upside
Target: $14.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MGX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.74 – $1.78
TARGET (TP)$14.50
STOP LOSS$1.62
RISK/REWARD1:91.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.51
52W High$4.40
52W Low$1.23
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $52.30M | $44.76M | $17.20M | $243,000 |
| Gross Profit | $52.30M | $-49,647,000 | $15.47M | $-144,000 |
| Gross Margin | 100.0% | -110.9% | 89.9% | -59.3% |
| Operating Income | $-88,901,000 | $-78,492,000 | $-44,640,000 | $-23,947,000 |
| Net Income | $-78,058,000 | $-68,255,000 | $-43,593,000 | $-21,442,000 |
| Net Margin | -149.3% | -152.5% | -253.4% | -8823.9% |
| EPS | $-2.09 | $-1.82 | $-1.16 | $-3.62 |
Company Overview
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$18
Average Target
↑ 898.4% Upside
Now
$6
Low
$18
Average
$25
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 7th 2024 | H.C. Wainwright | Initiation | Buy | $10 |
| May 2nd 2024 | JP Morgan | Downgrade | Neutral | $6← $16 |
| March 5th 2024 | TD Cowen | Initiation | Outperform | - |
| March 5th 2024 | BMO Capital Markets | Initiation | Outperform | $22 |
| March 5th 2024 | JP Morgan | Initiation | Overweight | $16 |
| March 5th 2024 | Jefferies | Initiation | Buy | $23 |
| March 5th 2024 | Chardan Capital Markets | Initiation | Buy | $21 |
| March 5th 2024 | Wells Fargo | Initiation | Overweight | $25 |
Earnings History & Surprises
MGXBeat Rate
63%
Last 8 quarters
Avg Surprise
+19.2%
EPS vs Estimate
Beats / Misses
5/3
Last 12 quarters
Latest EPS
$-0.55
Q4 2025
EPS Surprise History
Q1 24
+74.8%
$-0.51vs$-2.04
Q2 24
-25.3%
$-1.19vs$-0.95
Q3 24
+50.8%
$-0.29vs$-0.59
Q4 24
+35.7%
$-0.45vs$-0.70
Q1 25
-1.6%
$-0.63vs$-0.62
Q2 25
-9.7%
$-0.68vs$-0.62
Q3 25
+20.6%
$-0.54vs$-0.68
Q4 25
+8.3%
$-0.55vs$-0.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | $-0.58 | — | — | — |
Q4 2025 | Nov 11, 2025 | $-0.60 | $-0.55 | +8.3% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.68 | $-0.54 | +20.6% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.62 | $-0.68 | -9.7% | ✗ MISS |
Q1 2025 | Mar 17, 2025 | $-0.62 | $-0.63 | -1.6% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.70 | $-0.45 | +35.7% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.59 | $-0.29 | +50.8% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.95 | $-1.19 | -25.3% | ✗ MISS |
Q1 2024 | Feb 10, 2024 | $-2.04 | $-0.51 | +74.8% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | — | $-0.53 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.35 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.54 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.39 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.28 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-1.57 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-1.57 | — | — |
Latest News
Metagenomi shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 12, 2025, 04:53 PM
Metagenomi shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 11, 2025, 09:37 PM
Metagenomi Promotes Jian Irish To CEO, Appoints Willard Dere Board Chair
📈 PositiveBenzinga•Nov 11, 2025, 09:06 PM
Metagenomi Q3 EPS $(0.55) Beats $(0.60) Estimate, Sales $8.659M Beat $7.400M Estimate
📈 PositiveBenzinga•Nov 11, 2025, 09:04 PM
Metagenomi Presents New Preclinical Data From MGX-001 Hemophilia A Program, Demonstrating Curative FVIII Activity In Non-Human Primates
📈 PositiveBenzinga•Nov 11, 2025, 09:03 PM
Watching Metagenomi; Traders Mistakenly Assume CNBC Mentions Stock, CNBC Was Discussing An AI Company Named MGX Based In The UAE
📉 NegativeBenzinga•Oct 16, 2025, 03:53 PM
Metagenomi Shares Resume Trade
➖ NeutralBenzinga•Oct 16, 2025, 03:48 PM
Metagenomi Shares Halted On Circuit Breaker To The Upside, Stock Now Up 12.14%
📈 PositiveBenzinga•Oct 16, 2025, 03:35 PM
HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target
📈 PositiveBenzinga•Aug 19, 2025, 10:57 AM
Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $11
📈 PositiveBenzinga•Aug 15, 2025, 09:04 PM
Frequently Asked Questions about MGX
What is MGX's current stock price?
Metagenomi, Inc. Common Stock (MGX) is currently trading at $1.76 per share. The stock has moved +6.02% today.
What is the analyst price target for MGX?
The average analyst price target for MGX is $14.50, based on 1 analyst.
What sector is Metagenomi, Inc. Common Stock in?
Metagenomi, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MGX's market cap?
Metagenomi, Inc. Common Stock has a market capitalization of $0.07 billion, making it a small-cap company.
Does MGX pay dividends?
No, Metagenomi, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADVM
Adverum Biotechnologies, Inc.
$4.36
Mkt Cap: $0.1B
ALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
ARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
ATYR
aTyr Pharma, Inc.
$0.75
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
DTIL
Precision BioSciences, Inc.
$4.49
Mkt Cap: $0.1B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
KLRS
Kalaris Therapeutics Inc
$9.13
Mkt Cap: $0.2B
QNCX
Quince Therapeutics, Inc.
$3.57
Mkt Cap: $0.2B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
Explore stocks similar to MGX for comparison